Takahiro Kojima

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

Evan Y. Yu, Daniel P. Petrylak, Peter H. O’Donnell et al. · The Lancet Oncology · 2021 · 250 citations

Urology, Pd-l1 Inhibitors, Genitourinary Cancer +8

Support System of Cystoscopic Diagnosis for Bladder Cancer Based on Artificial Intelligence

Atsushi Ikeda, Hirokazu Nosato, Yuta Kochi et al. · Journal of Endourology · 2019 · 116 citations · Full text

Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling

Takahiro Kojima, Toru Shimazui, Shiro Hinotsu et al. · Oncogene · 2008 · 96 citations

Urology, Genitourinary Cancer, Malignant Disease +10

Increased serum nitrate levels in infants with atopic dermatitis

Shoichiro Taniuchi, Takahiro Kojima, K Hara et al. · Allergy · 2001 · 75 citations

Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab

Takashi Kobayashi, Katsuhiro Ito, Takahiro Kojima et al. · Cancer Science · 2020 · 72 citations · Full text

Urology, Genitourinary Cancer, Chemoresistant Urothelial Cancer +13